AMYLLY SANUELLY DA PAZ MARTINS1,#, MARLA DE CERQUEIRA ALVES2,#, ORLANDO ROBERTO PIMENTEL DE ARAÚJO3, FABIANA OLIVEIRA DOS SANTOS CAMATARI4, MARÍLIA OLIVEIRA FONSECA GOULART1,3,5, FABIANA ANDRÉA MOURA2,6,*
BIOCELL, Vol.47, No.11, pp. 2547-2566, 2023, DOI:10.32604/biocell.2023.043253
Abstract
Curcumin, a natural product, has exhibited promising effects in both animal models and clinical trials, interacting with a multitude of factors linked to Inflammatory Bowel Disease (IBD). These factors encompass cytokines, oxidative stress-associated enzymes, and modulation of the intestinal microbiota. Notably, curcumin has demonstrated therapeutic potential in animal models of colitis, wherein it exerts a negative regulatory influence on pivotal signaling pathways such as PI3/Akt, JAK/STAT, and β-catenin. Moreover, it inhibits the expression of pro-inflammatory enzymes and co-stimulatory molecules (including RANKL, ICAM-1, CD205, CD256, TLR4, among others), while curbing immune cell chemotaxis, thereby attenuating the characteristic neutrophil infiltration observed in… More >
Graphic Abstract
Login
Register
